,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2016', 'fs': 'Jan 2016', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JH0fUAG'}, 'Id': 'a0P2P000007JH0fUAG', 'Event_Date__c': '2016-01-07', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Jan 2016', 'Status_History__c': 'a132P000000Ar3cQAC'}, 'change': None}]",Jan 2016,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': 'The Committee recommended that the funding of rituximab be widened to include patients with severe, rapidly progressive myasthenia gravis, as a third-line treatment, with a high priority.   The Committee recommended that the funding of rituximab be widened to include patients with myasthenia gravis that is considered for disease that follows the usual time course but is refractory to alternative treatments, as a third-line treatment, with a low priority, and that the recommendation for this patient group be reviewed by PTAC after the results of the randomised controlled trial comparing rituximab with placebo become  available.', 'fs': 'The Committee recommended that the funding of rituximab be widened to include patients with severe, rapidly progressive myasthenia gravis, as a third-line treatment, with a high priority.   The Committee recommended that the funding of rituximab be widened to include patients with myasthenia gravis that is considered for disease that follows the usual time course but is refractory to alternative treatments, as a third-line treatment, with a low priority, and that the recommendation for this patient group be reviewed by PTAC after the results of the randomised controlled trial comparing rituximab with placebo become  available.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2016', 'fs': 'Aug 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2016.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JH0gUAG'}, 'Id': 'a0P2P000007JH0gUAG', 'Event_Date__c': '2016-08-11', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'High', 'Summary__c': 'The Committee recommended that the funding of rituximab be widened to include patients with severe, rapidly progressive myasthenia gravis, as a third-line treatment, with a high priority.   The Committee recommended that the funding of rituximab be widened to include patients with myasthenia gravis that is considered for disease that follows the usual time course but is refractory to alternative treatments, as a third-line treatment, with a low priority, and that the recommendation for this patient group be reviewed by PTAC after the results of the randomised controlled trial comparing rituximab with placebo become  available.', 'Formatted_Date__c': 'Aug 2016', 'Status_History__c': 'a132P000000ArAgQAK'}, 'change': None}, {'Summary': {'s': 'The Subcommittee recommended that PTAC review its recommendation for rituximab for myasthenia gravis based on the Subcommittee review of PTAC&#39;s minutes', 'fs': 'The Subcommittee recommended that PTAC review its recommendation for rituximab for myasthenia gravis based on the Subcommittee review of PTAC&#39;s minutes', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-neurological-subcommittee-minutes-2016-11.pdf"" target=""_blank"">Neurological Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-neurological-subcommittee-minutes-2016-11.pdf"" target=""_blank"">Neurological Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2016', 'fs': 'Nov 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Neurological Subcommittee at meeting Monday 7 November 2016.', 'fs': 'Clinical advice received from Neurological Subcommittee at meeting Monday 7 November 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JH0iUAG'}, 'Id': 'a0P2P000007JH0iUAG', 'Event_Date__c': '2016-11-07', 'Event_Description__c': 'Clinical advice received from Neurological Subcommittee at meeting Monday 7 November 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-neurological-subcommittee-minutes-2016-11.pdf"" target=""_blank"">Neurological Subcommittee minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'The Subcommittee recommended that PTAC review its recommendation for rituximab for myasthenia gravis based on the Subcommittee review of PTAC&#39;s minutes', 'Formatted_Date__c': 'Nov 2016', 'Status_History__c': 'a132P000000ArDVQA0'}, 'change': None}, {'Summary': {'s': 'The Committee noted the Subcommittee&#39;s advice that rituximab would not be used in an acute setting to control an exacerbation. The Committee noted  that, given this information, its previous recommendation for widening access to patients with severe, rapidly progressive myasthenia gravis, as a third line treatment, with a high priority (12.2 of the August 2016 minutes) would therefore not likely be a priority for funding as this is not the setting that it would be used in.  The Committee considered that given there has been no new robust evidence provided, its recommendation for funding for the &#39;severe refractory group&#39; (12.3 of the PTAC August 2016 minutes) remains with a low priority.', 'fs': 'The Committee noted the Subcommittee&#39;s advice that rituximab would not be used in an acute setting to control an exacerbation. The Committee noted  that, given this information, its previous recommendation for widening access to patients with severe, rapidly progressive myasthenia gravis, as a third line treatment, with a high priority (12.2 of the August 2016 minutes) would therefore not likely be a priority for funding as this is not the setting that it would be used in.  The Committee considered that given there has been no new robust evidence provided, its recommendation for funding for the &#39;severe refractory group&#39; (12.3 of the PTAC August 2016 minutes) remains with a low priority.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2017', 'fs': 'Feb 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 February 2017.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 February 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JHC5UAO'}, 'Id': 'a0P2P000007JHC5UAO', 'Event_Date__c': '2017-02-09', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 February 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Low', 'Summary__c': 'The Committee noted the Subcommittee&#39;s advice that rituximab would not be used in an acute setting to control an exacerbation. The Committee noted  that, given this information, its previous recommendation for widening access to patients with severe, rapidly progressive myasthenia gravis, as a third line treatment, with a high priority (12.2 of the August 2016 minutes) would therefore not likely be a priority for funding as this is not the setting that it would be used in.  The Committee considered that given there has been no new robust evidence provided, its recommendation for funding for the &#39;severe refractory group&#39; (12.3 of the PTAC August 2016 minutes) remains with a low priority.', 'Formatted_Date__c': 'Feb 2017', 'Status_History__c': 'a132P000000ArFZQA0'}, 'change': None}]",Aug 2016,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2016', 'fs': 'Aug 2016', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JH0hUAG'}, 'Id': 'a0P2P000007JH0hUAG', 'Event_Date__c': '2016-08-11', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Aug 2016', 'Status_History__c': 'a132P000000ArAlQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2017', 'fs': 'Feb 2017', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JHC6UAO'}, 'Id': 'a0P2P000007JHC6UAO', 'Event_Date__c': '2017-02-09', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2017', 'Status_History__c': 'a132P000000ArFcQAK'}, 'change': None}]",Aug 2016,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmacâ€™s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2018', 'fs': 'Jun 2018', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JHC7UAO'}, 'Id': 'a0P2P000007JHC7UAO', 'Event_Date__c': '2018-06-06', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2018', 'Status_History__c': 'a132P000000ArTaQAK'}, 'change': None}]",Jun 2018,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2019', 'fs': 'May 2019', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JHC8UAO'}, 'Id': 'a0P2P000007JHC8UAO', 'Event_Date__c': '2019-05-30', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Formatted_Date__c': 'May 2019', 'Status_History__c': 'a132P000000ArgSQAS'}, 'change': None}]",May 2019,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/news/consultation-2019-05-30-various/"" target=""_blank"">Consultation letter</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/news/consultation-2019-05-30-various/"" target=""_blank"">Consultation letter</a>', 'change': None}, 'Formatted_Date': {'s': 'Jun 2019', 'fs': 'Jun 2019', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JHC9UAO'}, 'Id': 'a0P2P000007JHC9UAO', 'Event_Date__c': '2019-06-14', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Links__c': '<a href=""https://www.pharmac.govt.nz/news/consultation-2019-05-30-various/"" target=""_blank"">Consultation letter</a>', 'Formatted_Date__c': 'Jun 2019', 'Status_History__c': 'a132P000000ArgyQAC'}, 'change': None}]",Jun 2019,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': 'Rituximab (Mabthera) access will be widened to include treatment of neuromyelitis optica spectrum disorders from 1 August 2019', 'fs': 'Rituximab (Mabthera) access will be widened to include treatment of neuromyelitis optica spectrum disorders from 1 August 2019', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-for-funding-in-the-neurology-immunosuppressants-diabetes-and-antithrombotic-therapy-areas/"" target=""_blank"">Notification letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-for-funding-in-the-neurology-immunosuppressants-diabetes-and-antithrombotic-therapy-areas/"" target=""_blank"">Notification letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jul 2019', 'fs': 'Jul 2019', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JHCAUA4'}, 'Id': 'a0P2P000007JHCAUA4', 'Event_Date__c': '2019-07-11', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-for-funding-in-the-neurology-immunosuppressants-diabetes-and-antithrombotic-therapy-areas/"" target=""_blank"">Notification letter</a></p>', 'Summary__c': 'Rituximab (Mabthera) access will be widened to include treatment of neuromyelitis optica spectrum disorders from 1 August 2019', 'Formatted_Date__c': 'Jul 2019', 'Status_History__c': 'a132P000000ArhLQAS'}, 'change': None}]",Jul 2019,False,True
